Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Hiru Corporation (HIRU; http://www.hirucorporation.com/) and its European subsidiary MindUp BioResearch (www.mindupbioresearch.com) comment on the recent research findings in the field of cancer treatments for multi-drug resistant non-small cell lung cancer (NSCLC). The MindUp Research team directs HIRU followers to the filing posted on Pink Sheets June 3, 2010 for details.

MindUp BioResearch points to the research on the drug Kevetrin. Kevetrin successfully overcame resistance and showed efficacy in tumors. On the other hand, only 50% of tested rats survived the same single dose of Kevetrin, suggesting some adverse effects on liver and kidney of rats. Mindup Bioresearch Group is of the opinion that MindUp drug Sulfinosine may lower the necessary dosage of Kevetrin, and prevent these negative effects.

Sulfinosine inhibits several important pathways necessary for tumor progression, and MindUp research suggests its usefulness in lung carcinoma indications, especially against multi-drug resistant phenotype, alone or in combination with new drugs.